Editing Digitoxin (section)

== Research ==
Digitoxin and related cardenolides display anticancer activity against a range of human [[cancer]] cell lines in vitro but the clinical use of digitoxin to treat [[cancer]] has been restricted by its narrow [[therapeutic index]].<ref>{{cite journal | vauthors = Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L | display-authors = 6 | title = Trial watch: Cardiac glycosides and cancer therapy | journal = Oncoimmunology | volume = 2 | issue = 2 | pages = e23082 | date = February 2013 | pmid = 23525565 | pmc = 3601180 | doi = 10.4161/onci.23082 }}</ref><ref>{{cite journal | vauthors = Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ | title = Digitoxin and its analogs as novel cancer therapeutics | journal = Experimental Hematology & Oncology | volume = 1 | issue = 1 | pages = 4 | date = April 2012 | pmid = 23210930 | pmc = 3506989 | doi = 10.1186/2162-3619-1-4 | doi-access = free }}</ref> Digitoxin [[glycorandomization]] led to the discovery of novel [[digitoxigenin]] neoglycosides which displayed improved anticancer potency and reduced inotropic activity (the perceived mechanism of general toxicity).<ref>{{cite journal | vauthors = Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS | title = Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 102 | issue = 35 | pages = 12305–10 | date = August 2005 | pmid = 16105948 | pmc = 1194917 | doi = 10.1073/pnas.0503270102 | bibcode = 2005PNAS..10212305L | doi-access = free }}</ref>